Study type: Human research · Status: Verified against declared source
Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 14 Randomized Controlled Trials
2025
Study scale: We included randomized, double- or single-blind, placebo-controlled clinical trials that evaluated the use of intravenous Cerebrolysin in adult patients (aged ≥18 years) with a diagnosis of acute ischemic stroke confirmed by imaging.
Abstract only: Open source record
Product or molecular entity relationships
- Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
Stroke remains a leading cause of mortality and long-term disability worldwide, with ischemic strokes comprising approximately 85% of all cases.
Methods
Over the past two decades, several meta-analyses have explored the effects of Cerebrolysin in acute ischemic stroke [5,6].
Scale or participants
We included randomized, double- or single-blind, placebo-controlled clinical trials that evaluated the use of intravenous Cerebrolysin in adult patients (aged ≥18 years) with a diagnosis of acute ischemic stroke confirmed by imaging.
Key findings
Cerebrolysin, a neurotrophic compound, has been investigated as a neurorestorative therapy in acute ischemic stroke, although findings are inconsistent due to limitations in study inclusion and outcome reporting.
Limitations and uncertainty
Cerebrolysin, a neurotrophic compound, has been investigated as a neurorestorative therapy in acute ischemic stroke, although findings are inconsistent due to limitations in study inclusion and outcome reporting.
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.